CompletedNot applicableNCT00814879

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

Studying Acquired immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Yale University
Principal Investigator
Michael J Kozal, MD
Yale University
Intervention
Raltegravir(drug)
Enrollment
60 target
Eligibility
18 years · All sexes
Timeline
20092013

Study locations (5)

Collaborators

Bristol-Myers Squibb · Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00814879 on ClinicalTrials.gov

Other trials for Acquired immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Acquired immunodeficiency

← Back to all trials